Blood Tau Trajectories Tied to Alzheimer Onset
Repeated blood tau measurements were associated with age at symptom onset among individuals at risk for Alzheimer disease
Longitudinal measurements of the blood-based tau biomarker (p-tau217) have shown a correlation with the timing of symptom onset in cognitively unimpaired individuals at risk for Alzheimer’s disease, according to a study published in Nature Medicine. Researchers utilized data from the Knight Alzheimer Disease Research Center and the Alzheimer’s Disease Neuroimaging Initiative to develop individualized ‘biomarker clock’ models. These models can estimate age at biomarker positivity, aiding in clinical trial design, although prediction errors preclude clinical decision-making for individuals at this stage.
1. p-tau217 biomarker linked to Alzheimer's onset. 2. Longitudinal measurements aid in understanding disease progression. 3. Individualized 'biomarker clock' models estimate age at positivity. 4. Data sourced from two major research cohorts. 5. Older individuals may progress to symptoms more rapidly. 6. Models can enhance clinical trial design but not for individual prognostication. 7. Variability in model performance noted with different assays.